Hvilken er prisen på Metagenomi, Inc. Common Stock (MGX)

Prisen på Metagenomi, Inc. Common Stock (MGX) er $1.21

Hva er markedsverdien på Metagenomi, Inc. Common Stock (MGX)

Markedsverdien på Metagenomi, Inc. Common Stock (MGX) er $45.55M

Metagenomi, Inc. Common Stock (MGX) P/B-forhold

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

År	P/B-forhold	Endre
Ikke nok data for de angitte datoene.

År

P/B-forhold

Endre

Ikke nok data for de angitte datoene.

Selskap	P/B-forhold	Forskjell i P/B-forhold	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	3.7087	-	US

Selskap

P/B-forhold

Forskjell i P/B-forhold

Land